SOPHiA GENETICS SA

NasdaqGS SOPH

SOPHiA GENETICS SA Free Cash Flow Yield on December 30, 2024: -24.17%

SOPHiA GENETICS SA Free Cash Flow Yield is -24.17% on December 30, 2024, a -25.50% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

SOPHiA GENETICS SA 52-week high Free Cash Flow Yield is -15.64% on June 03, 2024, which is 35.29% above the current Free Cash Flow Yield.
SOPHiA GENETICS SA 52-week low Free Cash Flow Yield is -26.02% on August 12, 2024, which is -7.67% below the current Free Cash Flow Yield.
SOPHiA GENETICS SA average Free Cash Flow Yield for the last 52 weeks is -19.89%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

NasdaqGS: SOPH

SOPHiA GENETICS SA

CEO	Dr. Jurgi Camblong M.B.A., Ph.D.
IPO Date	July 23, 2021
Location	Switzerland
Headquarters	Rue du Centre 172
Employees	430
Sector	Technology
Industries Software-as-a-Service (SaaS) Telehealth

Description

SOPHiA GENETICS SA operates as a healthcare technology company. The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, products, and services are used by hospital, laboratory, and biopharma worldwide. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Saint-Sulpice, Switzerland.

Key trends

Past 5 years